Aciclovir topical patch - Labtec

Drug Profile

Aciclovir topical patch - Labtec

Alternative Names: Acyclovir topical patch - Labtec; LabiPatch

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Labtec
  • Developer tesa Labtec
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpesvirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpesvirus-infections in Germany (Topical, Patch)
  • 20 Apr 2011 Clinical development is ongoing in Germany
  • 22 Jun 2010 GlaxoSmithKline acquires exclusive marketing rights for the aciclovir topical patch from Labtec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top